Cora Health Semaglutide Review

Cora Health publishes a complete price table rather than a starting price, names both pharmacies that might fill your prescription, and states plainly that what it sells is not therapeutically equivalent to the branded drugs. Our research (September 1, 2026) found one of the better-disclosed compounded operators in this comparison.

Important: These Are Compounded Medications

Cora Health states the position in the strongest form we look for:

"Compounded semaglutide and tirzepatide are prepared by a US-licensed 503A pharmacy under prescription from a licensed provider. Compounded medications are not FDA-approved and are not therapeutically equivalent to Ozempic®, Wegovy®, Mounjaro®, or Zepbound®."

That second clause is the one that matters. "Not FDA-approved" is common boilerplate; "not therapeutically equivalent" to the named brands is the specific claim most operators avoid, because it undercuts the implicit promise that a compounded copy performs like the original. The post-shortage caveat applies as everywhere: with the tirzepatide shortage resolved in October 2024 and semaglutide in early 2025, lawful 503A compounding now depends on a documented clinical reason for the individual patient rather than a shortage. Worth raising with the prescriber.

The Whole Price Matrix Is on the Page

"Compounded GLP-1, priced honestly. Every price. Every commitment length. No hidden fees, no 'starting at,' no surprises."

It delivers on that. Compounded semaglutide runs $175/month billed monthly, $145/month quarterly ($435), $120/month semi-annually ($720), or $99/month annually ($1,188). Compounded tirzepatide runs $225/month monthly, $199/month quarterly ($597), $175/month semi-annually ($1,050), or $135/month annually ($1,620). Publishing the monthly rate alongside the discounted annual rate is the honest way to present this. The $99 headline is real but it is the twelve-month prepay price; the no-commitment price is $175, and Cora shows both rather than burying the second. Every tier is stated to include the consultation, the medication, expedited shipping, provider monitoring and priority support, with no add-ons.

Both Pharmacies Are Named

"All medications are prepared by 503A state-licensed compounding pharmacies in the Cora Health network — specifically Hallandale Pharmacy (PCAB-accredited, Fort Lauderdale FL) and VialsRx (US-licensed 503A). Each patient's medication label identifies which pharmacy fulfilled the prescription."

Naming both, giving one's accreditation body, and committing to identify the actual compounder on the label is materially better than the category norm of silence. PCAB accreditation is a voluntary third-party compounding-quality standard, which is a real signal.

Clinical Structure

Providers come through the Wasef Health network, led by a board-certified internal medicine physician licensed in all 50 states, with clinical staff including a dual board-certified obesity medicine and emergency medicine physician. Cora is explicit about its own role:

"Cora Health connects patients with licensed, independent healthcare providers who make all prescribing decisions based on clinical evaluation."

Assessment takes about five minutes, provider review is stated at roughly 24 hours, and the service is LegitScript-certified, available in all 50 states, with HSA/FSA accepted and free shipping. Cancellation and pausing are handled by messaging the care team.

The One Claim We Would Push Back On

"$15,000/year saved. Ozempic® / Wegovy® at $1,000+/mo vs. Cora Essential from $99/mo."

Cora footnotes this correctly — "Savings calculated using published retail list prices" — but list price is close to a fiction in this market. Almost nobody pays $1,000 a month: NovoCare and LillyDirect sell brand-name product directly for a few hundred dollars a month, and insured patients pay a copay. Benchmarked against what a real cash-paying patient can actually get, the saving is a fraction of $15,000, and the comparison sits beside a product Cora itself says is not therapeutically equivalent to those brands.

What Is Not Published

No BMI or clinical eligibility threshold. No lab requirement before prescribing. No titration protocol or monitoring cadence beyond "ongoing provider monitoring." No founding year, and the refund policy is referenced rather than summarised on the pricing page — which matters for annual plans billed at $1,188 up front.